Molecule Name |
DB09239
|
DrugBank Groups |
Experimental
|
Cluster No |
2817
|
Smiles |
O=[N+]([O-])C1(=CC(=CC=C1)C2(C(=C(NC(=C2C(=O)OC)C)C)C(=O)OCCCN5(CCC(C3(=CC=CC=C3))(C4(=CC=CC=C4))CC5)))
|
Download |
mol2, pdbqt
|
TPSA |
468,56
|
Non-H Atoms |
45
|
Non-C/H Atoms |
9
|
Metal-Atoms |
0
|
Electronegative Atoms |
9
|
Stereo Centers |
1
|
Rotatable Bonds |
12
|
Rings Closures |
5
|
Small Rings |
5
|
Aromatic Rings |
3
|
Aromatic Atoms |
18
|
sp3-Atoms |
16
|
Symmetric atoms |
10
|
cLogS |
-5,516
|
MW |
609,721
|
cLogP |
4,6467
|
HBA |
9
|
HBD |
1
|
Ro5 violations |
1
|
Druglikeness |
3,0174
|
DrugScore |
0,322515677730875
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,8489
|
Caco-2 Permeability 2 |
0,6521
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Inhibitor
|
CYP450 2D6 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Strong inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,9816
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,9387
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,7567
|
Carcinogenicity (Three-class) |
Non-required
|